首页 日程列表
选择学组
选择日期
选择会场

抗肿瘤药物安全管理专场 Session3（论文交流）

2019-09-19 16:25-17:10

国宴三

学术日程
Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors
16:25-16:35
Toshio Shimizu    National Cancer Center Hospital
Efficacy and Safety of Selinexor in Recurrent Glioblastoma
16:35-16:45
Stephen Xie    德琪医药Antengene
Efficacy of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving high-dose cisplatin
16:45-16:55
常建华    中国医学科学院肿瘤医院深圳医院

16:55-17:00

提问

17:00-17:10

总结

 李进
同济大学附属东方医院